ylliX - Online Advertising Network
Company Ticker News

Roche Is Discussing Alzheimer’s Drug With FDA Following Regulators Controversial Approval Of Biogen’s Aduhelm, CEO Says

Roche Is Discussing Alzheimer's Drug With FDA Following Regulators Controversial Approval Of Biogen's Aduhelm, CEO Says

<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>

Aduhelm is expected to be a bestseller for Biogen and was the first Alzheimer’s drug to be granted “accelerated approval,” a decision the regulator’s experts criticized and said there was not enough evidence the drug actually worked.

...read full article on Forbes

ylliX - Online Advertising Network